^
Association details:
| Biomarker: | BCR-ABL1 fusion |
|---|---|
| Cancer: | Chronic Myeloid Leukemia |
| Drug: | Iclusig (ponatinib) (Multi-tyrosine kinase inhibitor) + fimepinostat (CUDC-907) (PI3K inhibitor, HDAC inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Effect of dual inhibition of histone deacetylase and phosphatidylinositol-3 kinase in Philadelphia chromosome-positive leukemia cells
Published date:
01/04/2020
Excerpt:
When ABL TKI treatment and CUDC-907 treatment were combined, significantly greater cytotoxicity was observed. Moreover, combined oral therapy with ponatinib (20 mg/kg/day) and CUDC-907 (30 mg/kg/day) greatly inhibited tumor growth compared to each drug alone.
DOI:
10.1007/s00280-019-04022-x
